CTRV - Hepion Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.5800
+0.0200 (+0.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.5600
Open3.5900
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range3.5450 - 3.6780
52 Week Range2.6900 - 61.6000
Volume139,180
Avg. Volume1,189,408
Market Cap5.875M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH

    Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that the U.S. Food and Drug Administration (“FDA”) has reviewed its Investigational New Drug (“IND”) application for CRV431 for the treatment of NASH and has authorized that the Company proceed with its planned IND opening study. This IND for NASH is in addition to the Company’s current open IND for hepatitis B virus (“HBV”).

  • 13 Disastrous Stocks That Could Get Even Worse
    Kiplinger

    13 Disastrous Stocks That Could Get Even Worse

    Investors love a turnaround play, and Wall Street is littered with stories of fortunes made betting on troubled companies.In the 1960s, American Express (AXP) was rumored to be near bankruptcy when Warren Buffett famously entered what is now one of his favorite Berkshire Hathaway positions. Apple (AAPL), which became the first U.S. company to hit $1 trillion in market value, absorbed more than a decade of losses during the 1980s and '90s before Steve Jobs helped turn the company around - aided by a $150 million investment from Microsoft (MSFT).But while every beat-up stock is a potential turnaround play, not every company achieves that potential. And losses can mount quickly for a stock that's already up against the ropes. So while you might be tempted to dabble in a potential comeback story or two, beware of some of the most common traps that end in disaster.Sometimes the issue is too much debt; rising interest costs and balloon payments can turn minor business setbacks into major liquidity challenges. Other times, once-powerful consumer brands are brought to their knees by management that's too slow to adapt to evolving consumer tastes.Certain areas of the market can be particularly prone to disasters. Start-up biotech stocks are risky because they're racing against the clock to bring new drugs to market before their cash runs out. Disappointing clinical trial result, in these cases, can cut a stock's value in half (or worse) within days. Chinese stocks are problematic, too, because of sometimes poor visibility and weak corporate governance.Here are 13 stocks to sell if you own them, or avoid if you're on the hunt for the next turnaround story. The companies themselves aren't necessarily an extinction threat, but for varying reasons, they're all on the brink of delivering more disastrous returns. SEE ALSO: Beware the Risks in These 13 Blue-Chip Stocks

  • GlobeNewswire

    ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA”

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that its Board of Directors has approved the change of the Company’s name and stock symbol to Hepion Pharmaceuticals, Inc. and “HEPA,” respectively. The Company’s new NASDAQ trading symbol will be effective as of the opening of trading on July 23, 2019, as will a new CUSIP number for the Company’s common stock of 426897104. “We derived the name ‘Hepion’ by combining the ancient Greek word for liver, ‘hepar,’ with ‘Epione,’ the goddess of soothing, or healing,” commented Dr. Robert Foster, the Company’s CEO.

  • GlobeNewswire

    ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced the filing of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for CRV431 for the treatment of NASH.

  • Benzinga

    Advice For New Traders When Momentum Dries Up

    The loss of momentum is unfortunate, but not devastating. Part of making a career of day trading is understanding that swings in momentum like this happen, and traders need to be prepared for dry spells. The first step in finding balance while momentum disappears is recognizing when reliable trading setups become less reliable.

  • Benzinga

    ContraVir Rebounds From Record Low On Positive FDA Feedback

    ContraVir Pharmaceuticals Inc (NASDAQ: CTRV) shares have been highly volatile of late, with the promise offered by its non-alcoholic steatohepatitis drug cushioning any downside for the stock. ContraVir, a thinly traded nanocap biotech, said Thursday after the close the FDA has given it positive feedback in response to its pre-IND meeting about its NASH pipeline asset CRV431. The positive feedback pertained to preclinical data for CRV431, with the regulatory body agreeing with ContraVir's proposed plan for further preclinical studies to support the development of the asset.

  • MarketWatch

    ContraVir's stock rockets off record low after 'positive feedback' on pre-IND for NASH

    Shares of ContraVir Pharmaceuticals Inc. rocketed 69% in active premarket trading Friday, to bounce off the previous session's record low close, after the biopharmaceutical company said it received "positive feedback" from the U.S. Food and Drug Administration in response to its pre-Investigational New Drug (pre-IND) meeting. Trading volume ballooned to over 760,000 shares, compared with the full-day average of about 1 million shares. The pre-IND meeting was with respect to the development of CRV431 for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH). The company said the feedback supports an IND submission for CRV431. "This IND submission for NASH will be in addition to our current existing IND for hepatitis B virus treatment," Chief Executive Robert Foster said. The stock has plunged 78% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 13% and the S&P 500 has advanced 18%.

  • Benzinga

    The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...

  • ContraVir’s stock suffers record plunge after seesaw week of upbeat drug studies, mistaken filings and withdrawals of withdrawals
    MarketWatch

    ContraVir’s stock suffers record plunge after seesaw week of upbeat drug studies, mistaken filings and withdrawals of withdrawals

    Shares of ContraVir Pharmaceuticals Inc. suffered a record Tuesday, to cap off a whipsaw week for investors that included upbeat results of a drug study, filings indicating the withdrawal, and a withdrawal of the withdrawal, of a share offering.

  • GlobeNewswire

    ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering

    ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced the pricing of a public offering with expected total gross proceeds of approximately $15.6 million, before deducting placement agent fees and other offering expenses payable by the Company. Roth Capital Partners is acting as the lead placement agent for the offering. Arcadia Securities, LLC is acting as co-placement agent for the offering.

  • Benzinga

    ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention

    ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) shares were rallying Monday on positive news related to its non-alcoholic steatohepatitis, or NASH, drug. ContraVir, which came under pressure Friday following ...

  • GlobeNewswire

    Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from its first study with human precision cut liver slice cultures. Liver disease was simulated in this unique experimental model by application of the potent, profibrotic molecules, TGFβ and PDGF.

  • Benzinga

    Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing

    June has been an eventful month for  ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ). Close on the heels of a 1-for-70 reverse stock split, which became effective June 3, the company has had incremental ...

  • GlobeNewswire

    ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B

    EDISON, N.J., June 11, 2019 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.

  • Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today
    InvestorPlace

    Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today

    ContraVir Pharmaceuticals (NASDAQ:CTRV) had a memorable Friday as the company's stock soared off the heels of a successful results regarding one of its treatments for liver disease.Source: Shutterstock The Edison, New Jersey-based pharmaceutical business today unveiled findings from a preclinical study in which CRV431, which is a novel cyclophilin inhibitor, significantly helped to decrease the extent of fibrosis in a second animal model of liver fibrosis. The term fibrosis refers to scarring of the liver, and it is a common symptom of non-alcoholic steatohepatitis (NASH), which causes impaired liver function.ContraVir Pharmaceuticals focuses mostly on developing therapeutic drugs to treat liver disease that arises from NASH. The company said that obeticholic acid (OCA), which is a semi-synthetic bile acid analogue drug, was approved for the treatment of primary biliary cholangitis (PBC), and it is being evaluated in Phase 3 trials by another company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe medication was used by a comparator drug within the study and did not decrease the extent of fibrosis in this study conducted by the company. This industry-standard model requires liver fibrosis to be induced in mice by administering carbon tetrachloride."This is the second animal model, and the fifth study overall, in which CRV431 consistently demonstrated a statistically significant reduction in fibrosis," said Dr. Robert Foster, Chief Executive Officer of ContraVir. "In addition, this study showed that CRV431 reduced fibrosis where OCA, a drug approved for PBC with potential to treat additional liver diseases, such as NASH, did not." More From InvestorPlace * 10 Stocks to Buy That Could Be Takeover Targets * 7 S&P 500 Stocks to Buy That Tore Up Earnings * The 10 Best Stocks for 2019 -- So Far Compare Brokers The post Why ContraVir Pharmaceuticals (CTRV) Is Skyrocketing Today appeared first on InvestorPlace.

  • Benzinga

    ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

    Shares of the nano-cap, thinly traded biotech  ContraVir Pharmaceuticals Inc (NASDAQ: CTRV ) were trading nearly 150-percent higher Thursday.  What Happened ContraVir, which focuses on therapies for liver ...

  • GlobeNewswire

    ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced findings from a preclinical study where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of fibrosis in a second animal model of liver fibrosis. Fibrosis, or scarring, of the liver is a hallmark symptom of NASH that results in impaired liver function.

  • GlobeNewswire

    ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split

    ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, announced today a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 70 effective May 31, 2019 (the “Effective Date”). The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market.

  • GlobeNewswire

    ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision

    ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, announced today that the Nasdaq Hearings Panel has granted the Company’s request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions. The Company is diligently working to evidence full compliance with all applicable requirements for continued listing on The Nasdaq Capital Market, in particular the $1.00 minimum bid price requirement.

  • GlobeNewswire

    ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced that management will present an update on the Company’s business at the 2019 ThinkEquity Conference on Thursday, May 2, 2019 at 1:30 p.m. Eastern Time in New York, NY. ContraVir is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).

  • Benzinga

    The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...

  • GlobeNewswire

    ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering

    ContraVir Pharmaceuticals, Inc. (“ContraVir,” the “Company,” “we,” “our” or “us”) (CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic viral infection, today announced the pricing of a public offering with expected total gross proceeds of approximately $2,140,000 before deducting placement agent fees and other offering expenses payable by the Company. Roth Capital Partners is acting as the lead placement agent for the offering. Brookline Capital Markets, a Division of CIM Securities, LLC is acting as co-placement agent for the offering.

  • GlobeNewswire

    ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™

    EDISON, N.J., April 11, 2019 -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of.

  • Again, Durham pharma loses a drug development partner
    American City Business Journals

    Again, Durham pharma loses a drug development partner

    One of Chimerix's development and commercial partners is out, disclosing this week it would be terminating a four-year-old licensing agreement after deciding to drop Chimerix's drug – the second time in less than five years the drug has been abandoned.